BackAIM ImmunoTech Overview

AIM ImmunoTech Total Assets

Track AIM ImmunoTech's total assets ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$12.73M
↑ 208.33% YoYΔ $8.60M vs prior year quarter

Peer trimmed avg / median

Loading

AIM ImmunoTech Total Assets History

Loading

AIM ImmunoTech vs. peers: Total Assets Comparison

Loading

AIM ImmunoTech Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AIM ImmunoTech (AIM) FAQ

AIM ImmunoTech's total assets stands at $13M as of June 2026. That compares with $4.1M in the prior-year period — up 208.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

AIM ImmunoTech reported $13M in total assets versus $4.1M a year earlier — a 208.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $4.1M in the prior-year period — up 208.3% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AIM ImmunoTech's total assets evolved across reporting periods, while the comparison chart places AIM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. AIM ImmunoTech's reading of $13M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.